10.22

18.45% 1.4369

Atara Biotherapeutics Inc (ATRA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ATRA? Forum Prognose

Schlusskurs vom Vortag:

$8.78

Offen:

$9.21

24-Stunden-Volumen:

457.67K

Relative Volume:

0.33

Marktkapitalisierung:

$87.51M

Einnahmen:

$120.77M

Nettoeinkommen (Verlust:

$32.69M

KGV:

3.5054

EPS:

2.9146

Netto-Cashflow:

$-50.94M

1W Leistung:

+118.49%

1M Leistung:

+123.66%

6M Leistung:

-16.60%

1J Leistung:

+60.74%

1-Tages-Spanne:

$9.0001

$10.66

1-Wochen-Bereich:

$4.72

$12.45

52-Wochen-Spanne:

$3.92

$19.14

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Firmenname

Atara Biotherapeutics Inc

Sektor

Healthcare (1111)

Branche

Biotechnology (619)

Telefon

805-623-4211

Adresse

1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA

Mitarbeiter

Twitter

@Atarabio

Nächster Verdiensttermin

2026-05-21

Neueste SEC-Einreichungen

ATRA's Discussions on Twitter

Compare ATRA vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ATRA Atara Biotherapeutics Inc	10.28	74.74M	120.77M	32.69M	-50.94M	2.9146
VRTX Vertex Pharmaceuticals Inc	449.33	110.45B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	716.62	74.73B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	815.05	50.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	293.30	38.03B	4.29B	577.22M	641.34M	4.2086
ONC Beone Medicines Ltd Adr	313.71	32.24B	5.36B	287.73M	924.18M	2.5229

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-13	Herabstufung	Canaccord Genuity	Buy → Hold
2023-11-09	Herabstufung	Evercore ISI	Outperform → In-line
2023-11-09	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-11-09	Herabstufung	Mizuho	Buy → Neutral
2022-07-20	Herabstufung	Citigroup	Neutral → Sell
2022-07-13	Herabstufung	JP Morgan	Overweight → Neutral
2022-07-13	Herabstufung	Stifel	Buy → Hold
2022-05-10	Herabstufung	Citigroup	Buy → Neutral
2021-05-13	Hochstufung	JP Morgan	Neutral → Overweight
2020-12-09	Herabstufung	Citigroup	Buy → Neutral
2020-12-08	Bestätigt	H.C. Wainwright	Buy
2020-11-10	Bestätigt	H.C. Wainwright	Buy
2020-06-30	Eingeleitet	Evercore ISI	Outperform
2020-06-15	Eingeleitet	H.C. Wainwright	Buy
2020-04-23	Hochstufung	Citigroup	Neutral → Buy
2019-11-08	Herabstufung	JP Morgan	Overweight → Neutral
2019-09-27	Herabstufung	Goldman	Neutral → Sell
2019-09-16	Herabstufung	Jefferies	Buy → Hold
2019-06-04	Hochstufung	Citigroup	Sell → Neutral
2019-05-30	Eingeleitet	ROTH Capital	Buy
2019-05-23	Eingeleitet	Stifel	Buy
2019-01-23	Eingeleitet	Mizuho	Buy
2018-04-10	Eingeleitet	JP Morgan	Overweight
2018-03-16	Eingeleitet	Guggenheim	Neutral
2018-03-05	Bestätigt	Jefferies	Buy
2018-02-28	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2018-02-15	Herabstufung	Citigroup	Neutral → Sell
2018-01-03	Hochstufung	Citigroup	Sell → Neutral
2017-10-06	Fortgesetzt	Goldman	Neutral

Alle ansehen

Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten

09:05 AM

Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors - GlobeNewswire

09:05 AM

09:00 AM

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. LawsuitATRA - PR Newswire

09:00 AM

May 11, 2026

Atara Biotherapeutics | 3: Initial statement of beneficial ownership of securities- EcoR1 Capital, LLC - Moomoo

May 11, 2026

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to ... - Caledonian Record

May 11, 2026

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

May 11, 2026

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Graphic Packaging Holding Company Investors to Secure Counsel Before Important Deadline in Securities Class Action – GPK - GlobeNewswire Inc.

May 11, 2026

Atara biotherapeutics director James Huang sells $3.16m in stock By Investing.com - Investing.com South Africa

May 11, 2026

Panacea funds cut Atara (ATRA) stake but remain 16.1% holder - Stock Titan

May 11, 2026

Atara biotherapeutics director James Huang sells $3.16m in stock - Investing.com

May 11, 2026

Panacea funds linked to Atara (NASDAQ: ATRA) director sell 313,446 shares - Stock Titan

May 11, 2026

EcoR1 Capital buys $4.74m in Atara Biotherapeutics stock - Investing.com

May 11, 2026

EcoR1 Capital (NASDAQ: ATRA) adds 507K Atara shares in open-market buy - Stock Titan

May 11, 2026

EcoR1 Capital (NASDAQ: ATRA) reports initial 1.04M-share Atara stake - Stock Titan

May 11, 2026

Atara Biotherapeutics, Inc. Sued for Securities Law - GlobeNewswire

May 11, 2026

MSN Money - msn.com

May 11, 2026

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire

May 11, 2026

Atara Biotherapeutics Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView

May 11, 2026

May 10, 2026

ROSEN, A TOP RANKED LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile

May 10, 2026

May 09, 2026

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile

May 09, 2026

ATRA Shareholders Have Opportunity to Lead Atara Biotherapeutics - The National Law Review

May 09, 2026

May 08, 2026

ATRA Upgraded by Canaccord Genuity -- Price Target Raised to $13 - GuruFocus

May 08, 2026